Daily Respiratory Research Analysis
Analyzed 231 papers and selected 3 impactful papers.
Summary
Analyzed 231 papers and selected 3 impactful articles.
Selected Articles
1. Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trial.
In a large PPF cohort, nerandomilast reduced the composite risk of acute exacerbation, respiratory hospitalization, or death over a mean 17-month observation, with stronger effects in patients not on background nintedanib. Safety and tolerability were favorable across both doses.
Impact: This extends prior FVC findings to hard clinical outcomes, suggesting nerandomilast may alter disease trajectory in PPF beyond lung function decline.
Clinical Implications: Nerandomilast may be a viable antifibrotic option to reduce exacerbations/hospitalizations and possibly mortality in PPF, particularly for patients not receiving nintedanib.
Key Findings
- Across 1,176 patients with PPF, nerandomilast 9 mg and 18 mg bid reduced time to first acute exacerbation, respiratory hospitalization, or death versus placebo (HR 0.78 and 0.77).
- Treatment effects were stronger in those not on background nintedanib (HR 0.69 and 0.65) than in those receiving nintedanib (HR 0.90 and 0.93).
- Mean on-treatment exposure was 15.1 months with a mean 17.0-month observation period; safety and tolerability were favorable.
Methodological Strengths
- Large international randomized trial population with extended time-to-event follow-up.
- Predefined composite key secondary endpoint reflecting clinically meaningful outcomes.
Limitations
- The analysis emphasizes secondary time-to-event endpoints; detailed blinding and allocation concealment are not described in the abstract.
- Effect modification by background nintedanib use suggests heterogeneity that warrants stratified analyses.
Future Directions: Confirm mortality and exacerbation benefits in stratified analyses and pragmatic trials, and clarify interactions with other antifibrotics and biomarkers to guide patient selection.
BACKGROUND: In the FIBRONEER-ILD trial in patients with progressive pulmonary fibrosis (PPF), nerandomilast 9 mg bid and 18 mg bid reduced the decline in forced vital capacity at week 52 compared with placebo (the primary endpoint). We assessed the effects of nerandomilast up to the final database lock. METHODS: Time to first acute exacerbation of ILD, hospitalisation for respiratory cause, or death (key secondary endpoint) and other time-to-event endpoints were assessed. RESULTS: 1176 patients, of whom 512 were taking background nintedanib, received nerandomilast or placebo. At final database lock, mean (sd) exposure to trial medication was 15.1 (5.7) months and mean (sd) observation period was 17.0 (4.1) months. Compared with placebo, the hazard ratio (95% CI) for the key secondary endpoint was 0.78 (0.61, 1.00) for nerandomilast 9 mg bid and 0.77 (0.60, 0.99) for nerandomilast 18 mg bid; hazard ratios were lower among patients not taking nintedanib (0.69 [0.49, 0.97] and 0.65 [0.46, 0.92], respectively) than among those taking background nintedanib (0.90 [0.63, 1.30] and 0.93 [0.65, 1.34], respectively). For death, the hazard ratio (95% CI) CONCLUSIONS: In the FIBRONEER-ILD trial in patients with PPF, nerandomilast reduced the risk of clinically important outcomes, including death, over the whole trial. Nerandomilast had a favourable safety and tolerability profile.
2. Liquid-liquid phase separation mediated immune evasion of respiratory syncytial virus against oligoadenylate synthetase-RNase L pathway.
RSV exploits liquid–liquid phase separation to form inclusion bodies that sequester dsRNA, preventing activation of the OAS–RNase L antiviral pathway. Disrupting LLPS releases dsRNA and restores pathway activation, revealing a structural immune-evasion mechanism and a potential therapeutic target.
Impact: This is a first-of-its-kind mechanistic demonstration that LLPS-driven inclusion bodies enable RSV to evade a central innate antiviral pathway. It advances fundamental virology and identifies a tractable biophysical process as a target.
Clinical Implications: Therapeutic strategies that disrupt RSV inclusion body formation or expose sequestered dsRNA could potentiate endogenous antiviral pathways and complement vaccines or monoclonal antibodies.
Key Findings
- RSV infection failed to activate the OAS–RNase L pathway, and ectopic RNase L activation did not suppress RSV replication.
- dsRNA was sequestered within LLPS-mediated inclusion bodies in infected cells; perturbing LLPS released dsRNA into the cytosol.
- Extracted dsRNA lacking LLPS shielding triggered activation of the OAS–RNase L pathway, indicating structural sequestration underlies immune evasion.
Methodological Strengths
- Direct visualization and functional perturbation of LLPS-driven inclusion bodies and dsRNA localization.
- Orthogonal assays linking dsRNA sequestration status to OAS–RNase L pathway activation and viral replication.
Limitations
- Findings are based on cell culture models without in vivo validation.
- The generalizability to other antiviral pathways or RSV strains requires further study.
Future Directions: Test LLPS-disrupting agents in vivo, define host/viral determinants of condensate formation, and evaluate synergy with existing RSV preventives or therapeutics.
Respiratory syncytial virus (RSV) infection is the major cause of severe respiratory illnesses in infants and older adults. RSV forms phase-separated biomolecular condensates called inclusion bodies (IBs), which serve as hubs for viral replication. However, the contribution of IBs to host immune response evasion remains elusive. We report that RSV IBs protect viral RNA from the 2'-5' oligoadenylate synthetase (OAS)-RNase L pathway, a critical antiviral defense mechanism that cleaves viral and cellular RNAs. RSV infection did not activate the OAS-RNase L pathway, and ectopically activated RNase L did not suppress viral replication. In RSV-infected cells, double-stranded RNA (dsRNA) was efficiently sequestered within liquid-liquid phase separation (LLPS)-mediated IBs, rendering its detection challenging. LLPS perturbation caused dsRNA release from IBs into the cytosol. dsRNA extracted from infected cells, which lacked LLPS shielding, triggered OAS-RNase L pathway activation. Thus, LLPS-driven IBs structurally sequester viral RNA, facilitating RSV to evade RNase-dependent genomic RNA degradation mediated by the OAS-RNase L antiviral pathway.
3. Bedside identification of subphenotypes in acute respiratory failure (PHIND): a multicentre, observational cohort study.
Using a near-patient benchtop immunoassay, clinicians prospectively assigned ARDS/AHRF patients to hyper- versus hypoinflammatory subphenotypes within hours, revealing a near-doubling of 60-day mortality in the hyperinflammatory group. This operationalizes precision stratification for future targeted trials.
Impact: It demonstrates real-time, actionable ARDS subphenotyping associated with outcome differences, addressing a key barrier to precision interventional studies.
Clinical Implications: Rapid bedside subphenotyping could guide enrollment and treatment allocation in ARDS trials and, ultimately, enable phenotype-specific supportive or pharmacologic strategies.
Key Findings
- Prospective, near-patient measurement of IL-6, TNFR1, and plasma bicarbonate enabled classification of 490 patients: 18% hyperinflammatory, 82% hypoinflammatory.
- 60-day mortality was 51% in hyperinflammatory vs 28% in hypoinflammatory patients (RR 1.8; adjusted OR 2.7).
- The benchtop immunoassay produced results in about 1 hour, making subphenotyping operationally feasible in acute care.
Methodological Strengths
- Prospective multicenter cohort with pre-specified parsimonious classifier and near-patient assay.
- Clinically relevant primary endpoint (60-day mortality) with adjusted analyses.
Limitations
- Observational design limits causal inference regarding treatment effects by subphenotype.
- Generalizability beyond UK/Ireland ICUs and across diverse racial groups may require further validation.
Future Directions: Embed the classifier in subphenotype-stratified RCTs to test targeted therapies; evaluate integration with EHR workflows and broader biomarker panels.
BACKGROUND: Acute respiratory distress syndrome (ARDS) is a clinically defined, biologically heterogeneous condition with no proven disease-modifying therapies. Retrospective analyses have identified two biologically distinct subphenotypes (hyperinflammatory and hypoinflammatory) of ARDS, with differing outcomes and responses to therapy. Rapid identification of these subphenotypes in an actionable timeframe has previously not been possible. The PHIND study aimed to prospectively identify these subphenotypes and to demonstrate differing 60-day mortality. METHODS: The PHIND study was a prospective, multicentre, observational cohort study conducted in intensive care units (ICUs) within the National Health Service in the UK and the Health Service Executive in Ireland. Adult patients aged 18 years and older with ARDS or acute hypoxaemic respiratory failure (AHRF) were enrolled within 72 h of onset of the syndrome. Eligible patients were required to be receiving invasive mechanical ventilation, non-invasive ventilation, or high-flow nasal oxygen. Plasma interleukin (IL-6) and soluble TNF receptor-1 (TNFR1) were quantified at enrolment using a near-patient benchtop immunoanalyser (Randox multiSTAT) with a run time of approximately 1 h. Together with plasma bicarbonate measured from an arterial blood sample, these values were used to prospectively determine subphenotypes on an individual patient basis using a validated parsimonious logistic regression model. The primary outcome was 60-day mortality. The study was registered on ClinicalTrials.gov, NCT04009330. FINDINGS: Between Nov 22, 2019, and Sept 28, 2023, 1853 patients from 30 centres were screened for eligibility. Of these, 1328 were excluded and 525 were recruited into the study, with 512 individuals included. 308 (60%) patients were male, 204 (40%) were female, and mean age was 57·0 years (SD 15·1). 443 (87%) patients were white, 18 (4%) were Black, and 16 (3%) were Asian. 490 were subphenotyped using the near-patient assay: 89 (18%) were classified as hyperinflammatory and 401 (82%) as hypoinflammatory. The primary outcome of 60-day mortality was measured in 486 patients after four patients withdrew consent for confirmation of vital status. 60-day mortality was significantly higher in the hyperinflammatory group (45 [51%] of 88) than in the hypoinflammatory group (111 [28%] of 398; risk ratio 1·8 [95% CI 1·4-2·4], p<0·0001). After adjustment, hyperinflammatory patients had increased odds of 60-day mortality (adjusted odds ratio 2·7 [95% CI 1·6-4·4], p=0·0002). INTERPRETATION: Rapid identification of ARDS inflammatory subphenotypes using a near-patient assay was feasible and associated with many clinical characteristics and outcomes consistent with those described in earlier retrospective studies, including mortality, prevalence of sepsis, and incidence of metabolic acidosis. These findings support the implementation of precision medicine approaches in ARDS and the urgent need for prospective, subphenotype-stratified interventional trials. FUNDING: Innovate UK, Randox Laboratories, and Belfast Health & Social Care Trust.